Role of S6K1 in regulation of SREBP1c expression in the liver

Biochemical and Biophysical Research Communications

Volumn 412, Issue 2, 2011, Pages 197-202

  Li, Shuying ^a,b   Ogawa, Wataru ^a   Emi, Aki ^a   Hayashi, Kumiko ^a   Senga, Yoko ^a   Nomura, Kazuhiro ^a   Hara, Kenta ^a   Yu, Demin ^b   Kasuga, Masato ^c  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Hepatocytes; Lipid synthesis; S6K1; SREBP1c

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOVIRUS VECTOR; BRANCHED CHAIN AMINO ACID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHOTRANSFERASE; RAPAMYCIN; S6 KINASE 1; SHORT HAIRPIN RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY ACID METABOLISM; FATTY LIVER; GENE EXPRESSION REGULATION; HYPERTRIGLYCERIDEMIA; LIPOGENESIS; LIVER CELL CULTURE; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CELL LINE; CHROMONES; FATTY LIVER; GENE EXPRESSION REGULATION; HEPATOCYTES; HYPERTRIGLYCERIDEMIA; LIVER; MICE; MICE, INBRED STRAINS; MORPHOLINES; OBESITY; PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA, SMALL INTERFERING; SIROLIMUS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADENOVIRIDAE; MAMMALIA; MUS;

EID: 80052031072     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.038     Document Type: Article

References (30)

1. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog. Lipid Res. 2001, 40:439-452.
2. Shimomura I., Matsuda M., Hammer R.E., Bashmakov Y., Brown M.S., Goldstein J.L. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 2000, 6:77-86.
3. Higuchi N., Kato M., Shundo Y., Tajiri H., Tanaka M., Yamashita N., Kohjima M., Kotoh K., Nakamuta M., Takayanagi R., Enjoji M. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 2008, 38:1122-1129.
4. Kohjima M., Enjoji M., Higuchi N., Kato M., Kotoh K., Yoshimoto T., Fujino T., Yada M., Yada R., Harada N., Takayanagi R., Nakamuta M. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 2007, 20:351-358.
5. Shimano H., Horton J.D., Shimomura I., Hammer R.E., Brown M.S., Goldstein J.L. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J. Clin. Invest. 1997, 99:846-854.
6. Brown M.S., Goldstein J.L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008, 7:95-96.
7. Shimomura I., Bashmakov Y., Ikemoto S., Horton J.D., Brown M.S., Goldstein J.L. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA 1999, 96:13656-13661.
8. Matsumoto M., Ogawa W., Teshigawara K., Inoue H., Miyake K., Sakaue H., Kasuga M. Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. Diabetes 2002, 51:1672-1680.
9. Miyake K., Ogawa W., Matsumoto M., Nakamura T., Sakaue H., Kasuga M. Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver. J. Clin. Invest. 2002, 110:1483-1491.
10. Dann S.G., Selvaraj A., Thomas G. MTOR complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med. 2007, 13:252-259.
11. Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., Griffiths J.R., Chung Y.L., Schulze A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008, 8:224-236.
12. Duvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., Vander Heiden M.G., MacKeigan J.P., Finan P.M., Clish C.B., Murphy L.O., Manning B.D. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
13. Li S., Brown M.S., Goldstein J.L. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl. Acad. Sci. USA 2010, 107:3441-3446.
14. Fenton T.R., Gout I.T. Functions and regulation of the 70kDa ribosomal S6 kinases. Int. J. Biochem. Cell Biol. 2011, 43:47-59.
15. Wu J.C., Merlino G., Fausto N. Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor α. Proc. Natl. Acad. Sci. USA 1994, 91:674-678.
16. Takashima M., Ogawa W., Hayashi K., Inoue H., Kinoshita S., Okamoto Y., Sakaue H., Wataoka Y., Emi A., Senga Y., Matsuki Y., Watanabe E., Hiramatsu R., Kasuga M. Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action. Diabetes 2010, 59:1608-1615.
17. Okamoto Y., Ogawa W., Nishizawa A., Inoue H., Teshigawara K., Kinoshita S., Matsuki Y., Watanabe E., Hiramatsu R., Sakaue H., Noda T., Kasuga M. Restoration of glucokinase expression in the liver normalizes postprandial glucose disposal in mice with hepatic deficiency of PDK1. Diabetes 2007, 56:1000-1009.
18. Minami T., Hara K., Oshiro N., Ueoku S., Yoshino K., Tokunaga C., Shirai Y., Saito N., Gout I., Yonezawa K. Distinct regulatory mechanism for p70 S6 kinase beta from that for p70 S6 kinase alpha. Genes Cells 2001, 6:1003-1015.
19. Matsumoto M., Ogawa W., Akimoto K., Inoue H., Miyake K., Furukawa K., Hayashi Y., Iguchi H., Matsuki Y., Hiramatsu R., Shimano H., Yamada N., Ohno S., Kasuga M., Noda T. PKCλ in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J. Clin. Invest. 2003, 112:935-944.
20. Hara K., Yonezawa K., Weng Q.P., Kozlowski M.T., Belham C., Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 1998, 273:14484-14494.
21. Shepherd P.R. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol. Scand. 2005, 183:3-12.
22. Gout I., Minami T., Hara K., Tsujishita Y., Filonenko V., Waterfield M.D., Yonezawa K. Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase beta containing a proline-rich region. J. Biol. Chem. 1998, 273:30061-30064.
23. Khamzina L., Veilleux A., Bergeron S., Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 2005, 146:1473-1481.
24. Miller A.M., Brestoff J.R., Phelps C.B., Berk E.Z., Reynolds T.H. Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of ob/ob mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:R1431-R1438.
25. Lee G.H., Proenca R., Montez J.M., Carroll K.M., Darvishzadeh J.G., Lee J.I., Friedman J.M. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996, 379:632-635.
26. Caballero B., Finer N., Wurtman R.J. Plasma amino acids and insulin levels in obesity: response to carbohydrate intake and tryptophan supplements. Metabolism 1988, 37:672-676.
27. Wijekoon E.P., Skinner C., Brosnan M.E., Brosnan J.T. Amino acid metabolism in the Zucker diabetic fatty rat: effects of insulin resistance and of type 2 diabetes. Can. J. Physiol. Pharmacol. 2004, 82:506-514.
28. Mathe D., Adam R., Malmendier C., Gigou M., Lontie J.F., Dubois D., Martin C., Bismuth H., Jacotot B. Prevalence of dyslipidemia in liver transplant recipients. Transplantation 1992, 54:167-170.
29. Galanis E., Buckner J.C., Maurer M.J., Kreisberg J.I., Ballman K., Boni J., Peralba J.M., Jenkins R.B., Dakhil S.R., Morton R.F., Jaeckle K.A., Scheithauer B.W., Dancey J., Hidalgo M., Walsh D.J. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 2005, 23:5294-5304. North Central Cancer Treatment Group.
30. Kahan B.D., Yakupoglu Y.K., Schoenberg L., Knight R.J., Katz S.M., Lai D., Van Buren C.T. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005, 80:749-758.